CSL is moving its American plasma centres back to Haemonetics, and the shares jumped 17.46%

CSL Haemonetics

Haemonetics rose 17.46% to US$119.47 on Thursday. CSL Plasma, the collection arm of Melbourne's CSL, now plans to move all its current US centres onto Haemonetics' NexSys collection machines by the end of 2027.

Why does a plasma machine matter so much? CSL collects plasma from donors and turns it into medicines. Each donation needs a machine and a single-use kit, and Haemonetics sells both. CSL runs more than 300 centres in America, so the kits mean repeat sales for years.

This is a reunion. In 2021 CSL told Haemonetics it would not renew their supply contract, which brought in US$88.6 million that year, or 10.2% of revenue. CSL moved its centres to Terumo's Rika machines and finished the switch in mid-2025.

Chart: Haemonetics' value sank, then CSL came back. Revenue for FY2022 to FY2026, US$m, left scale; market value at each year end, US$bn, right scale. The last point is the close before Thursday's 17.46% rise. — This story’s chart of the day.

The two signed a new agreement in August, covering only some centres, with the timing left open. Thursday's update covers all of them. The deal is still non-exclusive, and Haemonetics says the scope and timing can change.

What to watch

the November results call, where Haemonetics has promised to put a number on the deal. Until then the 17% rise is the market's estimate. Our read is that the non-exclusive clause matters, because CSL has switched suppliers once already.

This story ran in Counting the Revenue Friday 9 October’s edition, with the market snapshot, the other two stories, the numbers and the week ahead. Read the whole edition →

More in

All stories →

Monday 2 November Stryker cut its growth forecast as orthopaedic sales slowed, and the shares fell 6.38%
Friday 30 October Eli Lilly closed at a record after its weight-loss drugs lifted sales 39%
Saturday 10 October Humana's Medicare plans won back their stars, and the shares jumped 11.56%

General information and commentary only, not financial advice. It does not take account of your objectives, financial situation or needs, and reflects the author's own reading of public information at the time of writing, which may be wrong. Sharespective, its people and its clients may hold positions in the companies covered. Do your own research and talk to a licensed adviser.